{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:26:20Z","timestamp":1785198380414,"version":"3.55.0"},"reference-count":43,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This report presents a series of 16 patients who were admitted to the emergency department following confirmed intake of the potent synthetic cannabinoid ADB\u2010CHMINACA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The cases are drawn from a prospective observational study following the recreational use of synthetic cannabinoids. The clinical and analytical data were combined and submitted to a Poison Centre. The severity of poisoning was evaluated on the basis of clinical data, including follow\u2010up information. The present analysis was conducted exclusively on patients with analytically confirmed intake of ADB\u2010CHMINACA and treatment in emergency departments for acute adverse effects. Cases with additional relevant serum concentrations of other drugs of abuse that suggested relevant interactions were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Common clinical manifestations included panic attacks, tachycardia, agitation, vomiting and seizures. Most of the patients experienced these symptoms within minutes after inhaling this new psychoactive substance. Serum concentrations of ADB\u2010CHMINACA varied widely and ranged from 0.2\u201331 ng\/mL, without a clear correlation between severity of the poisoning and drug concentration. Severity of poisoning was moderate to severe, but all patients recovered. Notably, 1 of the patients developed a posterior reversible encephalopathy syndrome, a rare but serious neurological complication characterised by usually transient symptoms like headaches, seizures and altered mental state, often accompanied by brain oedema. In this case, the patient recovered after 4 days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Clinical presentations exhibited by patients with analytically confirmed intake of ADB\u2010CHMINACA showed similarities to previous reports; neuropsychiatric and cardiovascular symptoms were most prominent. Notable distinctions include the prevalence of panic attacks and trembling.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/bcp.70538","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T01:19:33Z","timestamp":1775006373000},"source":"Crossref","is-referenced-by-count":2,"title":["Acute toxicity of ADB\u2010CHMINACA \u2010 a case series of patients with pronounced central nervous symptoms including the posterior reversible encephalopathic syndrome"],"prefix":"10.1002","author":[{"given":"Maren","family":"Hermanns\u2010Clausen","sequence":"first","affiliation":[{"name":"Poisons Information Center Freiburg, Department of General Pediatrics, Adolescent Medicine and Neonatology, Center for Pediatrics Medical Center \u2013 University of Freiburg, Faculty of Medicine  Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Sommer","sequence":"additional","affiliation":[{"name":"Institute of Forensic Medicine, Forensic Toxicology, Medical Center \u2013 University of Freiburg, Faculty of Medicine  Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9017-0111","authenticated-orcid":false,"given":"Annette","family":"Zschiesche","sequence":"additional","affiliation":[{"name":"Institute of Forensic Medicine, Forensic Toxicology, Medical Center \u2013 University of Freiburg, Faculty of Medicine  Germany"},{"name":"Hermann Staudinger Graduate School, University of Freiburg  Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3081-4609","authenticated-orcid":false,"given":"Verena","family":"Angerer","sequence":"additional","affiliation":[{"name":"Institute of Forensic Medicine, Forensic Toxicology, HOCH Health Ostschweiz Kantonsspital St. Gallen  Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8356-2177","authenticated-orcid":false,"given":"Martin","family":"Scheu","sequence":"additional","affiliation":[{"name":"Institute of Forensic Medicine, Forensic Toxicology, Medical Center \u2013 University of Freiburg, Faculty of Medicine  Germany"},{"name":"Hermann Staudinger Graduate School, University of Freiburg  Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4753-2747","authenticated-orcid":false,"given":"Florian","family":"Eyer","sequence":"additional","affiliation":[{"name":"Department of Clinical Toxicology, TUM University Hospital, School of Medicine and Health, Technical University of Munich  Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3881-2883","authenticated-orcid":false,"given":"Johannes","family":"Nadler","sequence":"additional","affiliation":[{"name":"Poisons Information Center Freiburg, Department of General Pediatrics, Adolescent Medicine and Neonatology, Center for Pediatrics Medical Center \u2013 University of Freiburg, Faculty of Medicine  Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Auw\u00e4rter","sequence":"additional","affiliation":[{"name":"Institute of Forensic Medicine, Forensic Toxicology, Medical Center \u2013 University of Freiburg, Faculty of Medicine  Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"New psychoactive substances \u2013 the current situation in Europe (European Drug Report 2025).2025.https:\/\/www.euda.europa.eu\/publications\/european-drug-report\/2025\/new-psychoactive-substances_en"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1515\/cclm\u20102016\u20100831"},{"key":"e_1_2_10_4_1","unstructured":"L.VandamP.BorleL.MontanariT.SurmontA.PironaD.HedrichA.GallegosN.SingletonJ.MounteneyP.Griffiths.New psychoactive substances in prison: results from an EMCDDA trendspotter study.2018."},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.3002"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2023.111613"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1055\/s\u20100034\u20101387733"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360\u20100443.2012.04078.x"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1936"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13181\u2010016\u20100584\u20102"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2017.1393082"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2017.01.020"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2545"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.00464"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00414\u2010023\u201002995\u20102"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.3657"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11419\u2010025\u201000746\u2010z"},{"key":"e_1_2_10_18_1","unstructured":"EDND: Formal Notification ADB\u2010CHMINACA. European Monitoring Centre for Drugs and Drug Addiction.2025.https:\/\/ednd2.emcdda.europa.eu\/ednd\/substanceProfiles\/440"},{"key":"e_1_2_10_19_1","unstructured":"BuchlerIP HayesMJ HegdeSG et al.Indazole Derivatives.2009; WO2009106980A3."},{"key":"e_1_2_10_20_1","unstructured":"Anlage II BtMG \u2013 Einzelnorm. n.d.https:\/\/www.gesetze-im-internet.de\/btmg_1981\/anlage_ii.html"},{"key":"e_1_2_10_21_1","unstructured":"European Monitoring Centre for Drugs and Drug Addiction.ADB\u2010CHMINACA \u2013 Report on the Risk Assessment of N\u2010(1\u2010Amino\u20103 3\u2010Dimethyl\u20101\u2010Oxobutan\u20102\u2010Yl)\u20101\u2010(Cyclohexylmethyl)\u20101H\u2010Indazole\u20103\u2010Carboxamide in the Framework of the Council Decision on New Psychoactive Substances. Publications Office Of The European Union.2018"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.3109\/15563659809028940"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/jms.3020"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/jms.2026"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248\u2010016\u20100037\u20105"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.16177"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.14744\/nci.2014.44153"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2114482"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.05.006"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol\u20102021\u2010003194"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.936209"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/20009666.2020.1781349"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12560"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.22514\/SV152.092019.11"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000437297.05570.a2"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.4103\/1947\u20102714.185038"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2015.05.052"},{"key":"e_1_2_10_38_1","volume-title":"StatPearls","author":"Zelaya JE","year":"2025"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2016.1190016"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11419\u2010015\u20100272\u2010y"},{"key":"e_1_2_10_41_1","first-page":"709","volume-title":"Clin Toxicol","author":"Bottei E","year":"2016"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.5811\/westjem.2016.2.29519"},{"key":"e_1_2_10_43_1","unstructured":"EMCDDA\u2013Europol.Joint Report on a New Psychoactive Substance: N\u2010(1\u2010Amino\u20103 3\u2010Dimethyl\u20101\u2010Oxobutan\u20102\u2010Yl)\u20101\u2010(Cyclohexylmethyl)\u20101H\u2010Indazole\u20103\u2010Carboxamide (ADB\u2010CHMINACA). Publications Office Of The European Union. Luxembourg.2017."},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkw004"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70538","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bcp.70538","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70538","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T07:27:12Z","timestamp":1782113232000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":43,"alternative-id":["10.1002\/bcp.70538"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70538","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"article-number":"bcp.70538"}}